triptolide has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, G; Ma, R; Xu, Y | 1 |
| Cai, DF; Chen, YP; Gao, JP; Li, WW; Sun, S | 1 |
2 other study(ies) available for triptolide and Parkinsonian Disorders
| Article | Year |
|---|---|
[Protective effects of triptolide on the lipopolysaccharide-mediated degeneration of dopaminergic neurons in substantia nigra].
Topics: Animals; Diterpenes; Dopamine; Epoxy Compounds; Female; Inflammation Mediators; Lipopolysaccharides; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Phenanthrenes; Phytotherapy; Random Allocation; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2006 |
Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Biomarkers; CD11b Antigen; Cell Count; Cell Survival; Disability Evaluation; Diterpenes; Dopamine; Encephalitis; Epoxy Compounds; Gliosis; Herbicides; Immunosuppression Therapy; Immunosuppressive Agents; Male; Microglia; Neurons; Parkinsonian Disorders; Phenanthrenes; Rats; Rats, Sprague-Dawley; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase | 2008 |